An achondroplasia genetic test looks for a disease-causing change in the FGFR3 gene, usually the specific variant that replaces glycine with arginine at position 380 of the FGFR3 protein. The test can confirm achondroplasia when physical or X-ray findings are uncertain, distinguish it from related skeletal dysplasias, and identify the exact familial variant for reproductive testing. Most people with classic achondroplasia have one altered copy of FGFR3, while the other copy is unchanged. A positive result therefore usually confirms an autosomal dominant diagnosis, but the meaning depends on the variant classification, the person’s clinical findings, and whether one or both gene copies are affected. Testing is often performed on blood or saliva and does not require fasting. Results may guide genetic counseling, family testing, prenatal or embryo testing, and access to condition-specific care. They do not predict every complication, adult height, or treatment response by themselves.
- A positive FGFR3 result usually confirms achondroplasia when a pathogenic or likely pathogenic variant matches the person’s clinical and radiographic findings.
- More than 99% of classic cases involve FGFR3 p.Gly380Arg, most often caused by c.1138G>A and less often by c.1138G>C.
- A negative targeted test does not exclude every skeletal dysplasia; broader FGFR3 sequencing or a multigene panel may be needed for atypical features.
- No fasting or medication change is usually required for a blood, saliva, or cheek-swab DNA sample.
- An affected parent has a 50% chance of passing achondroplasia to each child when the other parent does not have a dominant skeletal dysplasia.
Table of Contents
- What the FGFR3 test detects
- When achondroplasia genetic testing is used
- Sample collection and laboratory methods
- Understanding positive, negative, and uncertain results
- Inheritance, family risk, and reproductive testing
- What the result can and cannot predict
- Next steps after testing
What the FGFR3 test detects
The test examines the FGFR3 gene, which gives cells instructions for making fibroblast growth factor receptor 3. This receptor helps regulate the growth and maturation of cartilage cells at the growth plate, where cartilage is gradually replaced by bone. In achondroplasia, a gain-of-function variant makes the receptor signal too strongly. The increased signaling slows the normal growth of long bones and contributes to the characteristic pattern of disproportionate short stature.
Classic achondroplasia is unusually genetically consistent. Nearly all affected people have the same amino-acid change, written p.Gly380Arg or p.G380R. The two DNA changes that can produce it are:
- c.1138G>A, which accounts for the great majority of cases
- c.1138G>C, which is much less common
Both are usually present in a heterozygous state, meaning one of the two FGFR3 copies carries the change. Because this narrow set of variants explains almost all classic cases, laboratories may begin with targeted testing of nucleotide 1138. That approach is fast and highly sensitive when the physical and radiographic findings are typical.
FGFR3 can also cause other conditions. Different variants are associated with hypochondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delay and acanthosis nigricans, and several craniosynostosis syndromes. A laboratory must therefore interpret the exact DNA change rather than treating every FGFR3 finding as achondroplasia. The same principle applies to any single-gene genetic test: the gene name alone does not determine the diagnosis; the specific variant and clinical context do.
A typical report lists the gene, transcript, DNA-level change, protein-level change, zygosity, and classification. It may also state whether the result is consistent with an autosomal dominant condition and whether family testing is recommended. Laboratories commonly classify variants as pathogenic, likely pathogenic, uncertain, likely benign, or benign. Only pathogenic and likely pathogenic variants that fit the person’s findings generally establish a molecular diagnosis.
When achondroplasia genetic testing is used
Genetic testing is most useful when it answers a specific diagnostic or family-planning question. Many newborns and children with classic achondroplasia can be diagnosed from their body proportions and characteristic skeletal X-rays. Molecular confirmation may still be helpful, especially when treatment eligibility, reproductive planning, or uncertainty about the diagnosis makes the exact gene result important.
Testing may be considered in the following situations:
- A newborn has rhizomelic limb shortening, macrocephaly, short fingers, or characteristic radiographic findings.
- Prenatal ultrasound shows shortened long bones, macrocephaly, a small chest, or another pattern suggesting a skeletal dysplasia.
- Clinical findings are mild or overlap with hypochondroplasia or another bone-growth disorder.
- A person with short stature never received a precise molecular diagnosis.
- A known familial FGFR3 variant needs to be checked in a relative, pregnancy, or embryo.
- A clinician or payer requires molecular confirmation before a targeted therapy is considered.
- Both prospective parents have achondroplasia or different dominant skeletal dysplasias and need a precise reproductive-risk assessment.
Testing should not replace a full skeletal-dysplasia evaluation. A medical geneticist or skeletal-dysplasia specialist may review birth history, growth measurements, head circumference, body proportions, neurologic findings, hearing, sleep, and imaging. The pattern matters because a positive molecular result should make biological and clinical sense.
Prenatal testing deserves particular care. Short femur length on ultrasound has many possible causes and does not by itself diagnose achondroplasia. The typical pattern may become more apparent in the late second or third trimester, especially in a pregnancy with average-stature parents and a new FGFR3 variant. When a parent has achondroplasia and the family variant is known, targeted testing can be planned earlier. Broader prenatal genetic testing may be appropriate when imaging suggests a skeletal condition but does not clearly identify which one.
Testing in an unaffected child or adult relative is rarely needed when the affected person’s variant arose de novo and neither parent has achondroplasia. Family testing becomes more useful when a parent has the condition, when mosaicism is suspected, or when the exact variant is needed for reproductive planning.
Sample collection and laboratory methods
Most achondroplasia testing uses DNA from a blood sample, saliva sample, or cheek swab. Blood often produces dependable DNA quality, but saliva and buccal samples may be suitable for many laboratories. Prenatal diagnostic testing may use chorionic villus sampling or amniotic fluid, while preimplantation testing uses a small number of cells biopsied from an IVF embryo.
No fasting is normally required. Medicines, vitamins, exercise, and time of day do not change the inherited DNA sequence. The laboratory may ask for a copy of a relative’s report when testing for a known familial variant. Providing the exact HGVS notation, such as c.1138G>A, reduces the risk of ordering the wrong assay.
Laboratories may use several strategies:
| Method | Best suited for | Main limitation |
|---|---|---|
| Targeted variant analysis | Typical achondroplasia or a known family variant | Does not assess most other FGFR3 variants or other genes |
| FGFR3 sequence analysis | Atypical features or suspected FGFR3-related disorder | May find a variant of uncertain significance |
| Skeletal-dysplasia multigene panel | Unclear diagnosis or overlapping skeletal findings | More complex results and possible unrelated findings |
| Exome or genome sequencing | Unexplained or complex cases after focused testing | May miss some variant types and generates broader data |
A targeted test may return in several days to a few weeks, although turnaround varies. Panels and sequencing studies often take longer. Prenatal laboratories may offer rapid testing when the result could affect time-sensitive pregnancy care.
Sample problems are uncommon but possible. A saliva specimen can fail if it contains too little human DNA, too much food residue, or bacterial contamination. A blood transfusion generally does not alter inherited testing from white blood cells in a lasting way, but recent stem-cell or bone-marrow transplantation can make blood DNA reflect the donor. In that situation, the laboratory may request cultured skin cells or another tissue. These details should be disclosed on the requisition.
Clinical laboratories typically confirm reportable variants and compare them with reference databases, published evidence, population frequency, and known disease mechanisms. A result from a consumer DNA service is not a substitute for a clinically validated genetic diagnostic test, particularly when prenatal decisions or medical treatment are involved.
Before ordering, it is worth checking whether the laboratory reports only the two common variants or reflexes automatically to broader sequencing after a negative result. Insurance authorization may depend on clinical notes, radiology reports, and a letter of medical necessity. Families should also ask how long the laboratory retains the sample, whether parental testing is included, and whether the report will be amended if the variant classification changes. These details do not alter the biology of the test, but they can prevent delays and duplicate sampling. For prenatal testing, the laboratory usually requires advance coordination, confirmation of the familial variant, and a maternal sample to detect contamination. A rush request should be arranged before the procedure rather than after the specimen has already been shipped.
Understanding positive, negative, and uncertain results
A result is interpreted by combining the laboratory finding with the person’s phenotype, imaging, and family history. The report wording can look definitive, but not every detected change has the same evidentiary strength.
Pathogenic or likely pathogenic variant
A heterozygous FGFR3 p.Gly380Arg result in a person with compatible findings usually confirms achondroplasia. “Likely pathogenic” means the laboratory has strong evidence that the variant causes disease, although the evidence may not meet every threshold for the word “pathogenic.” Both categories generally support clinical management when the result fits the presentation.
The report may say the variant is de novo if neither biological parent carries it in the tested sample and parentage is confirmed. De novo does not mean the change happened because of anything the parents did during pregnancy. It arose in an egg, sperm, or very early embryo. Most people with achondroplasia are born to average-stature parents because of such a new variant.
A positive result does not indicate disease severity on a numerical scale. There is no “high” or “low” FGFR3 level in this test. It identifies a sequence change; it does not measure receptor activity in the blood.
Negative result
A negative targeted c.1138 test makes classic achondroplasia much less likely, but the next step depends on the clinical picture. If the skeletal findings remain strongly suggestive, the clinician may request full FGFR3 sequencing or a skeletal-dysplasia panel. Another diagnosis may better explain the features, including hypochondroplasia, pseudoachondroplasia, osteogenesis imperfecta, or a different chondrodysplasia.
A negative test is especially limited when the wrong method was ordered. For example, testing only c.1138G>A would miss the less common c.1138G>C change. A report should state exactly which positions or regions were analyzed. It should also state whether deletion and duplication analysis was included, although large FGFR3 deletions are not a common cause of classic achondroplasia.
Variant of uncertain significance
A variant of uncertain significance, or VUS, means the available evidence cannot show whether the change causes disease. A VUS should not be used alone to confirm achondroplasia, rule it out, direct prenatal decisions, or test healthy relatives as though the diagnosis were known. The clinician may compare the variant with the person’s features, test selected family members, or ask the laboratory to review it later as evidence changes. The distinction is covered in more depth in VUS result interpretation.
Two disease-causing FGFR3 variants
When both parents have achondroplasia, a fetus can inherit the classic pathogenic variant from each parent. Biallelic, or homozygous, achondroplasia is much more severe and is usually life-limiting because of a very small chest and severe narrowing around the brainstem and upper spinal cord. A laboratory report that identifies two variants requires urgent interpretation by genetics, maternal-fetal medicine, neonatology, and skeletal-dysplasia specialists.
Inheritance, family risk, and reproductive testing
Achondroplasia follows an autosomal dominant inheritance pattern. One disease-causing FGFR3 copy is enough to cause the condition, and penetrance for the classic pathogenic variant is considered complete. The family risks differ depending on the parents’ diagnoses.
| Parents | Risk in each pregnancy |
|---|---|
| One parent has achondroplasia; the other has average stature and no dominant skeletal dysplasia | 50% achondroplasia and 50% no inherited familial variant |
| Both parents have achondroplasia | 25% average stature, 50% achondroplasia, 25% homozygous achondroplasia |
| Neither parent has achondroplasia; child has a confirmed de novo variant | Usually low for another child, but slightly above population risk because parental germline mosaicism is possible |
These percentages restart with every pregnancy. Having one affected or unaffected child does not change the probability for the next child. A person with achondroplasia also has a 50% chance of passing the variant to each biological child when the reproductive partner is not affected by another dominant skeletal condition.
The term autosomal dominant inheritance does not mean the condition becomes more severe in each generation. It describes how a variant is transmitted. Classic p.Gly380Arg achondroplasia has limited genotype-based prediction because most affected people share the same primary change, yet their medical needs and lived experiences still vary.
Once a familial variant is documented, several reproductive options may be discussed without assuming that one choice is right for every family:
- Natural conception with no prenatal testing
- Chorionic villus sampling, usually in the first trimester, for targeted fetal testing
- Amniocentesis, usually from the second trimester, for targeted fetal testing
- IVF with preimplantation genetic testing for a monogenic condition
- Donor egg, donor sperm, donor embryo, or adoption
- Pregnancy based on ultrasound findings with postnatal confirmation
Cell-free DNA methods for specific paternal or de novo FGFR3 variants are available in some specialized settings, but they are not the same as routine chromosome-focused noninvasive prenatal screening. Availability, validation, and whether the result is considered screening or diagnostic vary by laboratory and country. An invasive diagnostic sample may still be offered for confirmation.
Genetic counseling should be nondirective and respectful. Achondroplasia is compatible with a full life, and people with achondroplasia may view testing, disability, treatment, and reproductive options differently. Counseling should provide accurate medical information without framing average stature as the only acceptable outcome.
What the result can and cannot predict
A confirmed FGFR3 diagnosis helps clinicians organize surveillance, but it does not forecast an individual life in detail. The test can establish the molecular cause and clarify inheritance. It cannot reliably predict exact adult height, whether a person will need surgery, the severity of sleep apnea, hearing loss, leg bowing, spinal stenosis, pain, or psychosocial effects.
Medical follow-up matters because achondroplasia affects more than height. Important age-dependent concerns can include narrowing at the foramen magnum, central or obstructive sleep apnea, recurrent middle-ear disease, hearing loss, delayed motor milestones, thoracolumbar kyphosis, leg bowing, obesity, and lumbar spinal stenosis. These complications are assessed through examination, imaging, sleep studies, hearing tests, growth measurements, and symptoms—not by repeating the FGFR3 test.
The molecular result may support consideration of therapies that act on the FGFR3 growth-signaling pathway. It does not prove that a medicine will produce a specific number of centimeters of growth or prevent every complication. Treatment eligibility depends on age, open growth plates, regulatory approval, medical assessment, family preferences, access, and the product’s current prescribing information. Height response is only one outcome; function, comfort, safety, participation, and treatment burden also deserve attention.
The test also cannot determine whether a newly diagnosed infant has dangerous craniocervical compression. Urgent clinical assessment is needed for poor feeding, unusual weakness, episodes of turning blue, breathing pauses, persistent vomiting with neurologic signs, loss of skills, or abnormal limb movements. Genetic confirmation should never delay evaluation of symptoms that could indicate brainstem or spinal-cord compression.
A normal cognitive outcome is expected for most people with achondroplasia. Developmental motor milestones may occur later because of body proportions, joint laxity, and low muscle tone, not necessarily because of intellectual disability. If developmental, neurologic, or behavioral findings fall outside the expected pattern, clinicians should investigate them rather than assuming FGFR3 explains everything.
Next steps after testing
The most useful next step is a review with a clinician who understands skeletal dysplasia and can connect the result to the person’s age and findings. A genetics visit often includes checking that the reported variant matches the diagnosis, documenting family history, explaining recurrence risks, and deciding whether any relatives need testing.
After a positive result, care may include:
- Confirm the clinical diagnosis. Review growth, body proportions, skeletal imaging, and any features that are unusual for classic achondroplasia.
- Arrange age-appropriate surveillance. Infants need particular attention to the craniocervical junction, breathing, head growth, feeding, development, and hearing. Children and adults require monitoring tailored to sleep, spine, limbs, pain, weight, blood pressure, hearing, and function.
- Use achondroplasia-specific growth references. Average-population charts can misclassify expected body proportions and weight patterns.
- Discuss treatment without pressure. Review potential benefits, uncertainties, injections or procedures, monitoring, and personal priorities.
- Document the exact variant. Keep a copy of the laboratory report for future family, prenatal, or preimplantation testing.
- Seek genetic counseling before pregnancy when possible. This allows time to review partner diagnosis, testing options, and the special risks when both parents have skeletal dysplasia.
After a negative result, ask what was actually tested. The answer may be “only the common FGFR3 variants,” “the full coding region,” or “a broad panel.” A genetics professional can decide whether the phenotype supports additional testing. Repeating the same narrow test at another laboratory usually adds little unless there was a sample or technical concern.
After a VUS, avoid irreversible decisions based solely on the uncertain finding. Ask whether the laboratory offers periodic reanalysis, whether parental samples could help, and what diagnosis is supported by the clinical and radiographic evidence. Variant classifications can change, but many uncertain variants remain uncertain for years.
Families may also benefit from coordinated specialists, accessibility planning, school or workplace accommodations, and connection with peer-led organizations. Medical care should address health risks while supporting autonomy, inclusion, and the person’s own goals.
References
- Achondroplasia 2026 (Review)
- International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia 2022 (Consensus Statement)
- Clinical management and emerging therapies of FGFR3-related skeletal dysplasia 2022 (Review)
- Advances in the mechanism and therapies of achondroplasia 2024 (Review)
- International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia 2025 (Consensus Statement)
Disclaimer
This information is educational and cannot diagnose achondroplasia or interpret a specific laboratory report. Genetic results should be reviewed with a qualified clinician or genetic counselor, especially for prenatal testing, an uncertain variant, or a result showing two FGFR3 pathogenic variants. Seek urgent medical care for breathing pauses, blue episodes, new weakness, loss of skills, or other signs of possible neurologic compression.
